While the NA active site has been one of the primary targets for influenza antiviral (e.g., oseltamivir, zanamivir, and peramivir) development6, influenza vaccines have historically focused on eliciting antibodies that inhibit the receptor binding function of HA7. Here, XK is linked to influenza.